Publicaciones en colaboración con investigadores/as de Charles University in Prague (113)

2023

  1. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  2. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 64, Núm. 4

  3. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer

    The European respiratory journal, Vol. 62, Núm. 4

  4. Identification of novel genetic loci for risk of multiple myeloma by functional annotation

    Leukemia

  5. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

    Haematologica

  6. Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis

    Frontiers in Pharmacology, Vol. 14

  7. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

    Blood, Vol. 141, Núm. 6, pp. 579-591

  8. Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1600-1609

  9. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  10. Stratification of adolescents across mental phenomena emphasizes the importance of transdiagnostic distress: a replication in two general population cohorts

    European Child and Adolescent Psychiatry, Vol. 32, Núm. 5, pp. 797-807

  11. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

    Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 5, pp. 1172-1177